Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 13/20 | 1.00 |
| ▸ | SRC | P12931 | 12/20 | 1.00 |
| ▸ | ABL1 | P00519 | 11/20 | 1.00 |
| ▸ | EGFR | P00533 | 11/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 10/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 10/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 10/20 | 1.00 |
| ▸ | KIT | P10721 | 2/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.76 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.76 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.76 |
| ▸ | WEE1 | P30291 | 2/20 | 0.76 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.72 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.72 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.72 |
| ▸ | STK25 | O00506 | 1/20 | 0.72 |
| ▸ | GAK | O14976 | 1/20 | 0.72 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.72 |
| ▸ | JAK2 | O60674 | 1/20 | 0.72 |
| ▸ | STK10 | O94804 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29931141 | 1.00 | FGFR1 (1.00) | FGFR1SRCABL1EGFRPDGFRB | |
| SCHEMBL29658884 | 1.00 | FGFR1 (1.00) | FGFR1SRCABL1EGFRPDGFRB | |
| SCHEMBL2083189 | 0.91 | SRC (1.00) | FGFR1SRCABL1EGFRPDGFRB | |
| SCHEMBL2251121 | 0.88 | FGFR1 (0.78) | FGFR1SRCABL1EGFRPDGFRB | |
| SCHEMBL2082743 | 0.87 | FGFR1 (1.00) | FGFR1SRCABL1EGFRPDGFRB | |
| SCHEMBL1249524 | 0.87 | FGFR1 (1.00) | FGFR1SRCABL1EGFRPDGFRB | |
| SCHEMBL13498143 | 0.86 | FGFR1 (0.83) | FGFR1SRCABL1EGFRPDGFRB | |
| SCHEMBL16691033 | 0.86 | SRC (0.75) | FGFR1SRCABL1EGFRPDGFRB | |
| SCHEMBL6373835 | 0.86 | SRC (1.00) | FGFR1SRCABL1EGFRPDGFRB | |
| SCHEMBL5762318 | 0.85 | FGFR1 (1.00) | FGFR1SRCABL1EGFRPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312349-A1 | COMPOSITION AND METHODS OF TREATING INTRACELLULAR PATHOGEN INFECTION | UNIV HOSPITALS CLEVELAND MEDICAL CENTER (US) | 2025-10-09 | — | — | US | claimed |
| US-20220356494-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2022-11-10 | — | — | US | claimed |
| WO-2021126995-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | ENGINE BIOSCIENCES PTE. LTD. (SG) | 2021-06-24 | — | — | WO | claimed |
| EP-2233174-B1 | Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection | UNIV EMORY (US) | 2016-07-20 | — | — | EP | claimed |
| EP-2233174-A1 | Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection | Emory University (US) | 2010-09-29 | — | — | EP | claimed |
| US-20080220497-A1 | Modulation of protein functionalities | DECIPHERA PHARMACEUTICALS LLC | 2008-09-11 | — | — | US | claimed |
| EP-1907411-A2 | MODULATION OF PROTEIN FUNCTIONALITIES | Deciphera Pharmaceuticals, LLC. (US) | 2008-04-09 | — | — | EP | claimed |
| EP-1835934-A2 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-09-26 | — | — | EP | claimed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | claimed |
| WO-2007008917-A2 | MODULATION OF PROTEIN FUNCTIONALITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2007-01-18 | — | — | WO | claimed |
| EP-0823908-B1 | PYRIDO[2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2006-11-02 | — | — | EP | claimed |
| WO-2006071940-A2 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-07-06 | — | — | WO | claimed |
| WO-2005105097-A2 | PYRIDOPYRIMIDINES FOR TREATING INFLAMMATORY AND OTHER DISEASES | GPC BIOTECH AG (DE) | 2005-11-10 | — | — | WO | claimed |
| US-20250312349-A1 | COMPOSITION AND METHODS OF TREATING INTRACELLULAR PATHOGEN INFECTION | UNIV HOSPITALS CLEVELAND MEDICAL CENTER (US) | 2025-10-09 | — | — | US | disclosed |
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | WAVEBREAK INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | WAVEBREAK INC (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2006071940-A2 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-07-06 | — | — | WO | disclosed |
| WO-2005105097-A2 | PYRIDOPYRIMIDINES FOR TREATING INFLAMMATORY AND OTHER DISEASES | GPC BIOTECH AG (DE) | 2005-11-10 | — | — | WO | disclosed |
| US-20050009849-A1 | Pyridopyrimidine kinase inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2005-01-13 | — | — | US | disclosed |
| WO-2004063195-A1 | PYRIDOPYRIMIDINE KINASE INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009849-A1 | Pyridopyrimidine kinase inhibitors | MAP3K1, MAP3K19, MAP3K20 | FGFR1 192/4885SRC 335/4885ABL1 8/4885 |
| US-20220356494-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | SRC, BCOR, CTTN | FGFR1 1731/4885SRC 1/4885ABL1 18/4885 |
| US-20080220497-A1 | Modulation of protein functionalities | C1QBP, SERPINA6, CD2BP2 | FGFR1 4698/4885SRC 2604/4885ABL1 3158/4885 |
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | CPT2, PC, SREBF2 | FGFR1 2457/4885SRC 2896/4885ABL1 4428/4885 |
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | FGFR1 118/4885SRC 9/4885ABL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.